Servier could pay 320 million euros in Parkinson's tie-up

12 March 2019

Independent drugmaker Servier has teamed up with fellow French company Oncodesign (Euronext: ALONC) to investigate a new line of research in Parkinson’s disease.

The collaboration will cover the development of LRRK2 kinase inhibitors in the condition, and will see Servier granted the option to exclusively license one or several drug candidates as soon as they are approved to enter Phase I trials.

"LRRK2 inhibitors have the potential to act directly on the progression of the disease"Servier will fund the entire program, paying Oncodesign 3 million euros ($3.4 million) upfront and potentially up to 320 million euros in total with milestone payments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK